Ascendis Pharma Dividends and Buybacks
Dividend criteria checks 0/6
Ascendis Pharma does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-4.0%
Buyback Yield
| Total Shareholder Yield | -4.0% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Ascendis Pharma Takes A Big Price Cut On Skytrofa
Sep 05Ascendis Pharma A/S' (NASDAQ:ASND) Share Price Could Signal Some Risk
Jul 20
Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S
Apr 05Ascendis Pharma's Ambitious Vision 2030
Jan 11Ascendis Pharma: TransCon CNP Data Coming Q4
Sep 15Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH
Aug 31Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ASND's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ASND's dividend payments have been increasing.
Dividend Yield vs Market
| Ascendis Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ASND) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.4% |
| Analyst forecast (ASND) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ASND's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ASND's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ASND's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ASND has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 05:38 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ascendis Pharma A/S is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Michelle Gilson | Canaccord Genuity |
| Alethia Young | Cantor Fitzgerald & Co. |